Heart Failure (HF)
Heart failure (HF) is a syndrome caused by congestion and impairment of the heart's ability to pump blood. Our company is committed to developing cutting-edge diagnostics and therapeutics for the management of heart failure. As your reliable partner in heart failure research, we offer streamlined and comprehensive solutions to meet all your scientific research requirements.
Introduction to Heart Failure
Heart failure is a chronic and progressive condition characterized by the heart's diminished capacity to effectively pump blood, leading to decreased cardiac output and inadequate delivery of oxygen and nutrients to the body's organs and tissues. Heart failure affects over 6 million individuals in the United States, making it the primary cause of hospitalization among individuals aged 65 and above.
Fig. 1 Four major causes and time course of heart failure (HF). (Katagiri, Mikako, et al., 2022)Pathogenesis of Heart Failure
In heart failure, there are alterations in the structure or function of the heart, and in some cases, both. Heart failure can be considered the potential final stage of various heart diseases. The following are common causes of heart failure:
- Coronary artery disease
- Hypertension
- Cardiomyopathy
- Myocardial infarction
- Congenital heart defects
- Atrial fibrillation
- Valvular heart disease
- Myocarditis
- Excessive drinking
- Viral infection
- Use of chemotherapy drugs
- Obstructive sleep apnea
Targets of Heart Failure Therapy
Renin-Angiotensin-Aldosterone System (RAAS)
The RAAS plays a crucial role in regulating blood pressure and fluid balance, but its dysregulation can contribute to the progression of heart failure. Inhibitors of angiotensin-converting enzyme (ACE inhibitors) and angiotensin receptor blockers (ARBs) are commonly used to block the effects of the RAAS and reduce the workload on the heart.
Sympathetic Nervous
System
Individuals with heart failure have an imbalance in sympathetic nervous system activity, manifested by sympathetic overactivation, leading to increased heart rate, vasoconstriction, and sodium and water retention. Beta-blockers, including metoprolol and carvedilol, are commonly used to block sympathetic nerve activity and improve heart function.
Our Services
Our company has established comprehensive platforms for developing rare disease diagnostics and therapies, encompassing small molecule drug, cell therapy, gene therapy, therapeutic antibody, therapeutic peptide, and therapeutic protein. Through our dedicated platforms, we are fully devoted to advancing the development of innovative diagnostic tools and therapies for heart failure.
Recognizing the significance of animal disease models in the therapy development for heart failure, we offer our expertise in establishing animal models specifically tailored for heart failure. These models serve as invaluable tools to facilitate the safety evaluation and pharmacokinetics study of your drug candidates.
Animal Models of Heart Failure
| Induced Models | |||
|---|---|---|---|
| Induced heart failure models are created by subjecting animals to specific interventions or manipulations that mimic the pathological processes observed in human heart failure. Examples include surgical procedures, such as coronary artery ligation or transverse aortic constriction, which induce myocardial infarction or pressure overload, respectively. | |||
| Genetically Engineered Models | |||
| Our company is committed to the construction of genetically engineered models of heart failure. For example, our scientists use advanced gene-editing techniques to overexpress or delete genes involved in cardiac remodeling, contractility, or signaling pathways in animals to mimic certain aspects of heart failure. | |||
| Optional Models |
|
|
|
| Spontaneous Models | |||
| Spontaneous models of heart failure occur naturally in certain animal species and closely resemble human heart failure. For instance, certain dog breeds, such as the Doberman Pinscher, are prone to dilated cardiomyopathy, a condition that often leads to heart failure. These models allow researchers to study the natural progression of heart failure and potential genetic factors contributing to the disease. | |||
| Optional Species | Mice, Rats, Pigs, Dogs, Sheep, Non-Human Primates (Monkeys), Others | ||
Regardless of your current stage of research, we offer comprehensive research services tailored to your needs. If you are interested in our services, please don't hesitate to contact us for more information and a detailed quotation regarding the specific services you require.
References
- Katagiri, Mikako, et al. "Heart Failure Pathogenesis Elucidation and New Treatment Method Development." JMA Journal 5.4 (2022): 399-406.
- Schwinger, Robert HG. "Pathophysiology of heart failure." Cardiovascular diagnosis and therapy 11.1 (2021): 263.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.